Document Detail


Abnormal bradykinin signalling in fibroblasts deficient in the PIP(2) 5-phosphatase, ocrl1.
MedLine Citation:
PMID:  19172411     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The oculocerebrorenal syndrome of Lowe (Lowe syndrome) is an X-linked disorder of phosphatidylinositol metabolism characterized by congenital cataracts, renal proximal tubulopathy and neurological deficits. The disorder is due to the deficiency of the phosphatidylinositol 4,5-bisphosphate (PIP(2)) 5-phosphatase, ocrl1. PIP(2) is critical for numerous cellular processes, including cell signalling, actin reorganization and protein trafficking, and is chronically elevated in patients with Lowe syndrome. The elevation of PIP(2) cells of patients with Lowe syndrome provides the unique opportunity to investigate the roles of this phospholipid in fundamental cellular processes. We previously demonstrated that ocrl1 deficiency causes alterations in the actin cytoskeleton. Since actin remodelling is strongly activated by [Ca(+2)], which increases in response to IP(3) production, we hypothesized that altered calcium signalling might contribute to the observed abnormalities in actin organization. Here we report a specific increase in bradykinin-induced Ca(+2) mobilization in Lowe fibroblasts. We show that the abnormal bradykinin signalling occurs in spite of normal total cellular receptor content. These data point to a novel role for ocrl1 in agonist-induced calcium release.
Authors:
S F Suchy; J C Cronin; R L Nussbaum
Publication Detail:
Type:  Journal Article     Date:  2009-01-28
Journal Detail:
Title:  Journal of inherited metabolic disease     Volume:  32     ISSN:  1573-2665     ISO Abbreviation:  J. Inherit. Metab. Dis.     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-04-02     Completed Date:  2009-07-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7910918     Medline TA:  J Inherit Metab Dis     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  280-8     Citation Subset:  IM    
Affiliation:
Genetic Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA. sharon@genedx.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blotting, Western
Bradykinin / pharmacology*
Calcimycin / pharmacology
Calcium / metabolism
Calcium Signaling / genetics,  physiology*
Cell Line
Fibroblasts / drug effects,  enzymology,  physiology*
Histamine / pharmacology
Humans
Inositol 1,4,5-Trisphosphate Receptors / drug effects
Ionophores / pharmacology
Phosphoric Monoester Hydrolases / genetics,  physiology*
Platelet-Derived Growth Factor / pharmacology
Receptors, Bradykinin / drug effects
Tubulin / metabolism
Chemical
Reg. No./Substance:
0/Inositol 1,4,5-Trisphosphate Receptors; 0/Ionophores; 0/Platelet-Derived Growth Factor; 0/Receptors, Bradykinin; 0/Tubulin; 51-45-6/Histamine; 52665-69-7/Calcimycin; 58-82-2/Bradykinin; 7440-70-2/Calcium; EC 3.1.3.-/Phosphoric Monoester Hydrolases; EC 3.1.3.36/OCRL protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up.
Next Document:  Succinic semialdehyde dehydrogenase deficiency: lessons from mice and men.